Background: Antibiotic prophylaxis is recommended in cardiac surgery. Current debate concerns the type of antibiotic(s), dosing and the duration of prophylaxis.
Introduction
Placebo-controlled trials of antibiotic prophylaxis in cardiothoracic surgery have demonstrated a significant and large benefit to prophylaxis in the prevention of wound infections. 1 Since then, antibiotic prophylaxis is standard practice in cardiac surgery given the grave consequences of sternal wound infections. Contemporary debate exists on the optimal type of antibiotic(s), dosing and the duration of prophylaxis. Guidelines most commonly recommend standard or double-dose cefazolin or cefuroxime. 2 -7 Recommendations for duration diverge between general surgical guidelines that recommend ≤ 24 h post-operative prophylaxis, most commonly only pre-and intra-operative coverage, as for all operations 2,5 -7 and cardiac surgery-specific guidelines in the USA that advocate the prolongation of prophylaxis to 48 h postoperation. 3, 8 Surveys demonstrate that compliance with these or similar guidelines is very poor. 9 -11 Frequent deviations include the routine use of glycopeptides and longer than recommended duration. Variability in prophylaxis practices is larger in cardiac surgery than in other types of operations. 9 Two meta-analyses have previously summarized the evidence on antibiotic prophylaxis in cardiac surgery. 1, 12 Since these meta-analyses, more trials have been conducted and more controversies have been raised. We conducted a systematic review of all randomized controlled trials (RCTs) comparing different antibiotic prophylaxis strategies in cardiac surgery to address through meta-analyses the type, duration and dosing of prophylactic antibiotics in cardiac surgery.
Methods
We included RCTs, regardless of publication status, language or year of publication. We considered trials recruiting patients undergoing coronary artery bypass graft (CABG), valve, aortic or other cardiac surgery, excluding heart transplantation. If the trial addressed different types of operations, we extracted data for cardiac patients only; if not possible, we excluded the trial when .10% of patients had non-cardiac surgery. We included trials comparing any systemic single or combination antibiotic prophylaxis versus a different regimen, different dose or different durations of prophylaxis. We subsequently classified the trials into one or more of the comparisons listed below. We excluded trials comparing antibiotic prophylaxis versus placebo (since this was summarized in a previous review, 1 with no new trials since then), interventions limited to local antibiotics applied to the surgical wound and non-antibiotic interventions aimed at preventing surgical site infections (SSIs).
We defined the following comparisons:
(i) Additional Gram-negative coverage: prophylaxis providing enhanced Gram-negative spectrum of coverage (second-and third-generation cephalosporins, aminoglycosides and quinolones) versus antibiotics targeting mainly Gram-positive bacteria (first-generation cephalosporins, penicillin and methicillin derivatives, and glycopeptides). (ii) Prophylaxis duration: short versus longer prophylaxis duration where the difference between trial arms was ≥24 h. The primary outcome assessed was deep sternal wound infection (DSWI), considering that these infections are associated with the highest morbidity following cardiac surgery. We defined DSWI as deep incisional and organ/space SSIs according to CDC criteria, including mediastinitis, sternal osteomyelitis and purulent pericarditis. 13 Secondary outcomes included all sternal wound infections, sternal or limb SSI, sternal or limb deep SSI and SSIs requiring surgical intervention. When trials did not classify SSIs according to CDC criteria, we documented the study definitions and matched the study classification to CDC classes. Other secondary outcomes included SSIs caused by Gram-negative or Gram-positive bacteria and methicillin-resistant Staphylococcus aureus (MRSA), pneumonia, endocarditis, bacteraemias, all-cause mortality and adverse events, including Clostridium difficile-associated diarrhoea (CDAD). We extracted outcomes up to 3 months post-operation, allowing for the inclusion of SSIs detected post-discharge.
We searched for trials in The Cochrane Library, PubMed and LILACS databases. The last search in all databases was conducted in December 2010. In addition, we searched Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) 14 We adapted the search for other databases.
We extracted the study interventions, including timing preoperatively, intra-operatively and post-operative, and the effective duration of antibiotic prophylaxis after surgery considering the time of the last dose and the half-life of the antibiotic administered. We documented SSI definitions, their compatibility with current CDC classification for SSIs, 13 the methods of surveillance and diagnosis of SSIs, and whether and how post-discharge surveillance was conducted. We documented the duration of follow-up for SSIs and mortality. We assessed the risk of bias in included studies using the domain-based approach, classifying four items to adequate, not reported or inadequate: allocation concealment; allocation generation; double-blinding; and intention-to-treat analysis. We contacted trial authors to obtain missing data.
Two reviewers independently identified trials for inclusion and extracted the data from the included trials. The outcomes were extracted for all randomized patients, if possible. We calculated risk ratios (RRs) from individual trials with 95% confidence intervals (CIs) and pooled these using the Mantel-Haenszel (M-H) fixed-effect method for meta-analysis. We assessed heterogeneity in the meta-analysis visually, and using the x 2 test (P, 0.1 indicating significant heterogeneity) and the I 2 measure (I 2 .50% denoting inconsistency). 15 In meta-analyses including .10 trials, we assessed small study effects through funnel plot analysis. Analysis was performed using Review Manager 5.0. 16 Two-tailed Pearson correlation analysis was performed to examine correlations between all-cause mortality and other review-defined outcomes using IBM SPSS Statistics 19.
Results
Following the filtration of irrelevant, excluded and duplicate publications, we included 58 publications describing 59 different RCTs comparing different antibiotic prophylaxis regimens in cardiac surgery with one or more of the review-defined outcomes ( Figure 1 ). Twenty-five RCTs are included in the current systematic review that were not included in previous meta-analyses (Table S1 , available as Supplementary data at JAC Online). The trials were published between the years 1968 and 2010, and recruited a median of 200 patients per trial (range 30 -3047). The trials' location, years, risk of bias, study population, type of cardiac surgery, interventions, comparisons relevant for our review and full references are shown in Tables S1 and S2 (available as Supplementary data at JAC Online). References to excluded studies are listed in Table S3 (available as Supplementary data at JAC Online). Only three trials included children.
Nine trials were considered at low risk of bias with regard to allocation concealment, 41 did not report concealment methods and 9 were at high risk of bias using patients' identification number, admission number, birth dates, recruitment day or alternation. Twenty-one trials (35%) had a double-blind design. SSIs were defined using CDC criteria or study definitions that approximated CDC criteria in 26 trials (44%). Infections caused by MRSA and CDAD were rarely reported and thus could not be analysed. The timing of pre-operative prophylaxis was standardized by protocol in most trials: at induction in 28 trials; 30 -60 min before incision in 17; earlier than recommended in 4; and with incision in 1 trial. The other nine trials stated only that the pre-operative dose was administered before incision. Post-discharge surveillance for SSI was reported in 36 trials (61%) and follow-up was limited to hospitalization in 7 trials Systematic review (12%), while the others did not define the duration of follow-up for SSIs. Ethics Committee approval was reported in 37 trials and informed consent in 36 trials (61%).
Additional Gram-negative coverage
Thirty-six trials contributed to the comparison between antibiotic prophylaxis providing an enhanced Gram-negative spectrum of coverage versus prophylaxis aimed mainly at Gram-positive bacteria.
There were no significant differences in DSWIs or all other categories of SSIs (Table 1) . Also, when the outcome assessed was SSIs caused by Gram-negative bacteria, there was no significant difference (RR 1.46, 95% CI 0.97 -2.19). There were no significant differences with regard to endocarditis or bacteraemia. Antibiotic prophylaxis comprising Gram-negative coverage led to a significantly lower rate of post-operative pneumonia and significantly lower all-cause mortality. The effect was most prominent when Gram-negative coverage was provided by a b-lactam in both comparisons: RR 0.68 (95% CI 0.51 -0.90) for pneumonia ( Figure 2 ) and RR 0.66 (95% CI 0.47-0.92) for mortality ( Figure 3 ). The b-lactam was a second-or third-generation cephalosporin in all studies but one. 17 There was no significant heterogeneity in both analyses. The funnel plot was symmetric in both analyses. 
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Prophylaxis duration
Twenty-three trials compared prophylaxis regimens with an effective post-operative coverage ≥24 h longer than the comparator arm. There were no differences between the RRs for trials comparing the same or different antibiotic(s) in the longduration versus short-duration study arms (analyses not shown); thus, trials comparing the same and different antibiotic regimens were pooled for the analyses presented. 
Systematic review
Shorter duration prophylaxis was associated with a higher rate of DSWI. The difference originated from studies in which the short-duration arm was ≤ 24 h post-operation (RR 1.83, 95% CI 1.25 -2.66) without heterogeneity (Figure 4 ). There were no significant differences between short versus longer prophylaxis when the short-duration arm provided .24 h postoperative coverage (Table 2 ). In this group of studies, the mean post-operative prophylaxis duration in the short-duration arm was 48 h (30 -60 h). The same trends were observed for all other SSI categories, with a statistically significant benefit for longer versus ≤ 24 h post-operative prophylaxis for any sternal wound infection, surgical intervention for SSI and also for endocarditis. The difference between prophylaxis duration ≤24 h post-operation and longer prophylaxis was on account of SSIs caused by Gram-positive bacteria (Table 2) . SSIs caused by Gram-negative bacteria were unaffected by the prophylaxis duration. The duration of prophylaxis did not affect pneumonia, bacteraemia and all-cause mortality.
Glycopeptide versus b-lactam
Ten trials compared a glycopeptide versus a b-lactam. The glycopeptide was administered alone in all trials. DSWIs occurred more frequently with glycopeptides when there was a difference in postoperative prophylaxis duration of ≥24 h between the study arms (Table 3 ). This analysis was dominated by one large study showing an advantage of cefazolin compared with teicoplanin, in which the effective duration of cefazolin was longer than that of teicoplanin. 18 There was no significant difference in DSWI, with a trend in favour of glycopeptides, when the effective postoperative prophylaxis duration was similar for the glycopeptide and the b-lactam. A similar dichotomy was observed for the Figures S1 and S2 , available as Supplementary data at JAC Online). The advantage of glycopeptides, when these were given for a total duration similar to the b-lactam, was statistically significant for any SSI (sternal or limb) and surgical interventions for SSI. There were no significant differences for pneumonia, bacteraemia and all-cause mortality.
Cephalosporin-based versus penicillin-based prophylaxis regimen
Eight trials were identified. The penicillin arm included a combination of two different penicillins in two trials and penicillin combined with an aminoglycoside in two trials.
There was no statistically significant difference between cephalosporins and penicillins for DSWIs and most other review-defined outcomes (Table 4) . A result in favour of cephalosporins for bacteraemia was of low certainty due to the paucity of trials and heterogeneity (I 2 ¼ 52%). Since penicillinbased prophylaxis is considered nowadays as a modality to decrease CDAD, 19 we attempted to extract this outcome for this comparison. Only one trial reported on CDAD and no events were documented. 20 None of the trials reported on diarrhoea in general.
Antibiotic dosing
Four trials compared low versus higher doses of the same antibiotic. The pre-operative dose was doubled or tripled in all trials, the intra-operative dose was increased in two and the post-operative dose was also doubled in two (Table S2, available as Supplementary data at JAC Online). Only few and disparate outcomes were reported; thus, we pooled the SSI categories that were reported in the studies (most commonly any SSI). There was no advantage of higher antibiotic dosing (RR 0.79, Systematic review 95% CI 0.32 -1.93), with broad CIs corresponding to the paucity of trials and outcomes.
Other analyses
Two of the trials identified for this review were not included in the comparisons above. One compared two second-generation cephalosporins (cefonicid versus cefamandole) 21 and the other compared cefalotin versus clindamycin, 19 both for a similar postoperative duration. No significant differences were observed in each of the trials for all review-defined outcomes.
Across all studies, all-cause mortality was significantly correlated with rates of bacteraemia in the study (R ¼ 0.791, P, 0.001, 23 trials), endocarditis (R ¼ 0.556, P ¼ 0.005, 24 trials) and pneumonia (R ¼ 0.449, P ¼ 0.009, 26 trials). There were no significant correlations between DSWI or other SSI categories and all-cause mortality.
Discussion
This systematic review of .40 years of RCTs assessing different antibiotic prophylaxis regimens in cardiac surgery addressed several pertinent issues. . SSI rates were not affected. Second-and third-generation cephalosporins were most frequently compared with a first-generation cephalosporin or a penicillinase-resistant penicillin. The number needed to treat with a second-or third-generation cephalosporin instead of a first-generation cephalosporin/penicillin to prevent one pneumonia was 74 patients (95% CI 43-269), given a control event rate of 4.4%. To prevent one death the number was 88 patients (95% CI 49-396), given a control event rate of 3.4%. The reduction in mortality observed in this analysis was probably related to the effect on pneumonia. Rates of pneumonia in these studies were correlated with mortality and previous studies have shown that post-operative pneumonia and ventilator-associated pneumonia (VAP) are strong and significant predictors for death following cardiac surgery, and are not rare events. 22 -24 Antibiotic prophylaxis in the critical care setting, even short-duration selective decontamination regimens, results in decreased rates of pneumonia and mortality. 25, 26 For perioperative prophylaxis to have an effect on the incidence of pneumonia implies that some post-operative pneumonias are acquired very early, during or immediately after surgery, at the time the patient is intubated or shortly after extubation. One study included in our review showed that colonization immediately after intubation (pre-operatively) predicted pneumonia. 27 In the same study, as in the overall meta-analysis, a longer duration of prophylaxis did not affect the incidence of pneumonia.
Duration of prophylaxis
The rationale given for prolonging the duration of antibiotic prophylaxis in cardiac surgery includes the pharmacokinetic/ pharmacodynamic changes caused the bypass process, hypothermia and loss of blood. 3, 8 We show that a prophylaxis duration of ≤24 h post-operation was inferior to longer regimens with regard to DSWI, any sternal SSI, surgical intervention for SSI and endocarditis. These results are compatible with those of a recent meta-analysis; 28 however, both rely on studies comparing different antibiotic regimens. In our analysis, no difference between 48 h versus longer regimens was found for all outcomes. The disadvantages of prolonging prophylaxis include the induction of resistant bacteria that may affect the individual patient and surrounding patients, the induction of CDAD, and other adverse events. These were mostly not assessed in existing trials. In an observational study, a prophylaxis duration .48 h was associated with significantly higher rates of acquired antibiotic resistance. 29 Given a 2.2% event rate for DSWIs with short prophylaxis and an RR of 1.83 for long versus short prophylaxis, a sample of .3000 patients is necessary to show this advantage in a new trial. Thus, it is unlikely that a trial comparing the same antibiotics and powered to confirm or disprove these findings will be conducted. Prophylaxis should not be given for .48 h; there is indirect evidence that continuation until 48 h post-operatively might be beneficial.
Glycopeptides versus b-lactams
In some centres, an increasing frequency of SSIs caused by MRSA and coagulase-negative staphylococci has led to the use of glycopeptide prophylaxis. 30, 31 In the previous meta-analysis comparing glycopeptides with b-lactams, an advantage of b-lactams was observed with regard to chest infections. 12 However, when we stratified the overall analysis by prophylaxis duration (which we showed to affect SSIs), glycopeptides were not inferior to b-lactams when given for a similar post-operative duration, and were superior to b-lactams with regard to any SSI and surgical interventions for SSI. Only four trials included in this analysis reported on the prevalence of MRSA among SSIs and RRs for any SSI tended to favour glycopeptides with increasing prevalence of MRSA (meta-regression not shown); however, the paucity of trials limits this analysis. Thus, the threshold of MRSA in a hospital, or more specifically among SSIs in cardiac surgeries, in which glycopeptide prophylaxis is justified, cannot be determined with the current evidence.
Antibiotic dosing
Higher than standard dosing has been suggested in cardiac surgery given that cardiopulmonary bypass increases the volume of distribution and elimination of the antibiotics. 4 Only four trials were identified that specifically assessed this intervention by comparing low versus high doses of the same antibiotic. These were small trials (total of 435 patients included in this analysis), reporting few and disparate outcomes. Compiling all SSIs that were reported in these studies, no advantage of higher dosing could be shown. However, the power of this sample to detect even a double rate of DSWI with lower dosing (from a baseline of 1.2% observed in RCTs included in our review) was ,10%. Thus, prophylactic antibiotic dosing must currently rely on biological considerations rather than evidence.
Other findings
In all analyses, antibiotic prophylaxis affected mainly SSIs caused by Gram-positive bacteria, while those SSIs caused by Systematic review
Gram-negative bacteria were less affected by the type of prophylaxis regimen. Post-operative pneumonia, bacteraemia and endocarditis were correlated with mortality, but SSIs were not. SSIs incur significant morbidity and costs, but rarely lead to death. We found no difference for cephalosporin-based versus penicillin-based prophylaxis regimens, which we hypothesized might affect CDAD rates. However, CDAD rates were not consistently reported in this and other analyses.
Limitations
The trials included in our review span a long period. Throughout the years surgical techniques and post-operative management have changed, as have the antibiotics used and bacterial resistance patterns. SSI definitions and surveillance methods varied. Yet, there was no statistical heterogeneity in the analyses showing benefit presented in our review and study year had no effect on RRs for these outcomes (meta-regression analyses not shown), which lends support to the pooled effects. It is not certain that second-or third-generation cephalosporins would provide the same protection against VAP nowadays as shown in existing trials. Most trials used methods associated with an unclear risk of bias. We could not assess the effects of allocation concealment on the results due to the paucity of trials using low-risk-of-bias methods.
Implications for clinical practice
Second-or third-generation cephalosporins are as efficacious as first-generation cephalosporins with regard to SSI prevention, and resulted in a lower rate of post-operative pneumonia and lower all-cause mortality. They should be the preferred agents for perioperative cardiac surgery prophylaxis. Current evidence points at a possible advantage of a prophylaxis duration of 48 h post-operation compared with shorter duration prophylaxis, but this is based on comparisons of different antibiotics. There is not enough evidence to conclude whether higher than normal dosing is beneficial. Glycopeptides might be warranted in locations where MRSA is prevalent and are non-inferior to b-lactams. The timing of administration of the first antibiotic dose has not been assessed in RCTs, but observational studies have shown convincing data on the importance of giving the first dose within 30 -60 min pre-operatively. 32 
Implications for further research
A contemporary trial confirming the advantage of prophylactic antibiotics comprising a Gram-negative spectrum of coverage with regard to pneumonia and mortality might be warranted. In locations where MRSA is prevalent, the addition of a glycopeptide to a second-or third-generation cephalosporin should be assessed. To confirm the advantage of a longer prophylaxis duration, prophylaxis given pre-and intra-operatively should be compared with the same antibiotic given for 48 h postoperatively. All future trials should report SSIs by CDC criteria to allow for comparability. 13 Given the results shown in our review, all trials should report on pneumonia and all-cause mortality.
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